Reducing cardiovascular risk in diabetes. Which factors to modify first? (Q34228809)

31 July 2017

1 reference

title

Reducing cardiovascular risk in diabetes. Which factors to modify first? (English)

1 reference

31 July 2017

R G Spanheimer

1

1 reference

PubMed ID

11317467

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

31 July 2017

Postgraduate Medicine

1 reference

31 July 2017

109

1 reference

31 July 2017

26-30, 33-6

1 reference

31 July 2017

4

1 reference

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

31 July 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2001.04.904

21 January 2018

Identifiers

DOI

10.3810/PGM.2001.04.904

1 reference

31 July 2017

1 reference

PubMed ID

11317467